Acurx Historical Financial Ratios

ACXP Stock

USD 0.41 0.01 2.38%

Acurx Pharmaceuticals is presently reporting on over 69 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.0203 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Acurx Pharmaceuticals LLC financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acurx Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Acurx Financial Ratios Analysis

Acurx Pharmaceuticals LLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Acurx Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Acurx financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Acurx Pharmaceuticals history.

Acurx Pharmaceuticals Financial Ratios Chart

At this time, Acurx Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year. As of 03/30/2025, Tangible Book Value Per Share is likely to grow to 39.96, though Operating Cash Flow Per Share is likely to grow to (610.28).

Ptb Ratio Book Value Per Share Average Payables Pb Ratio

Add Fundamental

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from Acurx Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Acurx Pharmaceuticals LLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acurx Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2022	2024	2025 (projected)
Company Equity Multiplier	1.28	6.27	6.59
Effective Tax Rate	1.01E-4	9.1E-5	8.7E-5

Company Equity Multiplier Effective Tax Rate

Acurx Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A	Current Ratio	Tangible Book Value Per Share	Shareholders Equity Per Share	Debt To Equity	Capex Per Share
Ptb Ratio		-0.57	0.55	0.55	0.61	1.0	0.55	-0.96	0.56	-0.58	-0.86	-0.55	-0.86	0.42	0.2	-0.87	-0.85	-0.04	-0.87	0.55	-0.9	-0.42	-0.57	-0.57	0.52	0.55
Book Value Per Share	-0.57		-1.0	-1.0	-0.6	-0.57	-1.0	0.39	-1.0	-0.18	0.74	1.0	0.74	-0.15	-0.91	0.71	0.7	-0.77	0.71	-1.0	0.2	-0.26	1.0	1.0	-0.95	-1.0
Free Cash Flow Yield	0.55	-1.0		1.0	0.61	0.55	1.0	-0.38	1.0	0.2	-0.73	-1.0	-0.73	0.11	0.92	-0.69	-0.69	0.78	-0.69	1.0	-0.2	0.28	-1.0	-1.0	0.93	1.0
Operating Cash Flow Per Share	0.55	-1.0	1.0		0.61	0.55	1.0	-0.38	1.0	0.2	-0.73	-1.0	-0.73	0.11	0.92	-0.69	-0.69	0.78	-0.69	1.0	-0.2	0.28	-1.0	-1.0	0.93	1.0
Average Payables	0.61	-0.6	0.61	0.61		0.61	0.61	-0.43	0.61	-0.01	-0.74	-0.61	-0.74	-0.12	0.49	-0.72	-0.7	0.41	-0.72	0.61	-0.52	0.2	-0.6	-0.6	0.47	0.61
Pb Ratio	1.0	-0.57	0.55	0.55	0.61		0.55	-0.96	0.56	-0.58	-0.86	-0.55	-0.86	0.42	0.2	-0.87	-0.85	-0.04	-0.87	0.55	-0.9	-0.42	-0.57	-0.57	0.52	0.55
Free Cash Flow Per Share	0.55	-1.0	1.0	1.0	0.61	0.55		-0.38	1.0	0.2	-0.73	-1.0	-0.73	0.11	0.92	-0.69	-0.69	0.78	-0.69	1.0	-0.2	0.28	-1.0	-1.0	0.93	1.0
Roic	-0.96	0.39	-0.38	-0.38	-0.43	-0.96	-0.38		-0.38	0.67	0.7	0.38	0.7	-0.43	0.01	0.72	0.69	0.26	0.72	-0.38	0.94	0.6	0.39	0.39	-0.35	-0.38
Net Income Per Share	0.56	-1.0	1.0	1.0	0.61	0.56	1.0	-0.38		0.2	-0.73	-1.0	-0.73	0.11	0.92	-0.69	-0.69	0.78	-0.69	1.0	-0.2	0.28	-1.0	-1.0	0.93	1.0
Cash Per Share	-0.58	-0.18	0.2	0.2	-0.01	-0.58	0.2	0.67	0.2		0.39	-0.2	0.39	-0.71	0.49	0.46	0.47	0.69	0.46	0.2	0.74	0.87	-0.18	-0.18	0.19	0.2
Pocfratio	-0.86	0.74	-0.73	-0.73	-0.74	-0.86	-0.73	0.7	-0.73	0.39		0.73	1.0	-0.41	-0.5	1.0	0.99	-0.31	1.0	-0.73	0.66	0.08	0.74	0.74	-0.69	-0.73
Capex To Operating Cash Flow	-0.55	1.0	-1.0	-1.0	-0.61	-0.55	-1.0	0.38	-1.0	-0.2	0.73		0.73	-0.12	-0.92	0.69	0.69	-0.79	0.69	-1.0	0.19	-0.28	1.0	1.0	-0.94	-1.0
Pfcf Ratio	-0.86	0.74	-0.73	-0.73	-0.74	-0.86	-0.73	0.7	-0.73	0.39	1.0	0.73		-0.41	-0.5	1.0	0.99	-0.31	1.0	-0.73	0.66	0.08	0.74	0.74	-0.69	-0.73
Income Quality	0.42	-0.15	0.11	0.11	-0.12	0.42	0.11	-0.43	0.11	-0.71	-0.41	-0.12	-0.41		-0.07	-0.45	-0.49	-0.22	-0.45	0.11	-0.3	-0.66	-0.15	-0.15	0.28	0.12
Roe	0.2	-0.91	0.92	0.92	0.49	0.2	0.92	0.01	0.92	0.49	-0.5	-0.92	-0.5	-0.07		-0.45	-0.45	0.95	-0.45	0.92	0.17	0.55	-0.91	-0.91	0.85	0.92
Ev To Operating Cash Flow	-0.87	0.71	-0.69	-0.69	-0.72	-0.87	-0.69	0.72	-0.69	0.46	1.0	0.69	1.0	-0.45	-0.45		1.0	-0.25	1.0	-0.69	0.69	0.15	0.71	0.71	-0.65	-0.69
Pe Ratio	-0.85	0.7	-0.69	-0.69	-0.7	-0.85	-0.69	0.69	-0.69	0.47	0.99	0.69	0.99	-0.49	-0.45	1.0		-0.25	1.0	-0.69	0.66	0.16	0.7	0.7	-0.65	-0.69
Return On Tangible Assets	-0.04	-0.77	0.78	0.78	0.41	-0.04	0.78	0.26	0.78	0.69	-0.31	-0.79	-0.31	-0.22	0.95	-0.25	-0.25		-0.25	0.78	0.4	0.75	-0.77	-0.77	0.75	0.79
Ev To Free Cash Flow	-0.87	0.71	-0.69	-0.69	-0.72	-0.87	-0.69	0.72	-0.69	0.46	1.0	0.69	1.0	-0.45	-0.45	1.0	1.0	-0.25		-0.69	0.69	0.15	0.71	0.71	-0.65	-0.69
Earnings Yield	0.55	-1.0	1.0	1.0	0.61	0.55	1.0	-0.38	1.0	0.2	-0.73	-1.0	-0.73	0.11	0.92	-0.69	-0.69	0.78	-0.69		-0.2	0.28	-1.0	-1.0	0.93	1.0
Net Debt To E B I T D A	-0.9	0.2	-0.2	-0.2	-0.52	-0.9	-0.2	0.94	-0.2	0.74	0.66	0.19	0.66	-0.3	0.17	0.69	0.66	0.4	0.69	-0.2		0.59	0.2	0.2	-0.1	-0.19
Current Ratio	-0.42	-0.26	0.28	0.28	0.2	-0.42	0.28	0.6	0.28	0.87	0.08	-0.28	0.08	-0.66	0.55	0.15	0.16	0.75	0.15	0.28	0.59		-0.26	-0.26	0.27	0.28
Tangible Book Value Per Share	-0.57	1.0	-1.0	-1.0	-0.6	-0.57	-1.0	0.39	-1.0	-0.18	0.74	1.0	0.74	-0.15	-0.91	0.71	0.7	-0.77	0.71	-1.0	0.2	-0.26		1.0	-0.95	-1.0
Shareholders Equity Per Share	-0.57	1.0	-1.0	-1.0	-0.6	-0.57	-1.0	0.39	-1.0	-0.18	0.74	1.0	0.74	-0.15	-0.91	0.71	0.7	-0.77	0.71	-1.0	0.2	-0.26	1.0		-0.95	-1.0
Debt To Equity	0.52	-0.95	0.93	0.93	0.47	0.52	0.93	-0.35	0.93	0.19	-0.69	-0.94	-0.69	0.28	0.85	-0.65	-0.65	0.75	-0.65	0.93	-0.1	0.27	-0.95	-0.95		0.94
Capex Per Share	0.55	-1.0	1.0	1.0	0.61	0.55	1.0	-0.38	1.0	0.2	-0.73	-1.0	-0.73	0.12	0.92	-0.69	-0.69	0.79	-0.69	1.0	-0.19	0.28	-1.0	-1.0	0.94

Click cells to compare fundamentals

Acurx Pharmaceuticals Account Relationship Matchups

Acurx Pharmaceuticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	28.96	3.56	5.89	10.4	0.0214	0.0203
Book Value Per Share	0.27	1.21	0.68	0.37	38.06	39.96
Free Cash Flow Yield	(0.0428)	(0.11)	(0.18)	(0.2)	(789.2)	(749.74)
Operating Cash Flow Per Share	(0.34)	(0.49)	(0.7)	(0.77)	(642.41)	(610.28)
Pb Ratio	28.96	3.56	5.89	10.4	0.0214	0.0203
Free Cash Flow Per Share	(0.34)	(0.49)	(0.7)	(0.77)	(642.41)	(610.28)
Roic	(1.66)	(1.03)	(1.65)	(3.12)	(2.81)	(2.95)
Net Income Per Share	(0.46)	(1.24)	(1.12)	(1.15)	(872.54)	(828.91)
Cash Per Share	0.32	1.27	0.84	0.59	0.23	0.22
Pocfratio	(23.34)	(8.81)	(5.71)	(4.95)	(0.001267)	(0.00133)
Pfcf Ratio	(23.34)	(8.81)	(5.71)	(4.95)	(0.001267)	(0.00133)
Roe	(1.7)	(1.02)	(1.65)	(3.12)	(22.93)	(21.78)
Ev To Operating Cash Flow	(22.42)	(6.22)	(4.5)	(4.19)	(9.1E-4)	(9.56E-4)
Pe Ratio	(17.01)	(3.48)	(3.56)	(3.33)	(9.33E-4)	(9.8E-4)
Return On Tangible Assets	(1.43)	(0.96)	(1.29)	(1.89)	(3.66)	(3.84)
Ev To Free Cash Flow	(22.42)	(6.22)	(4.5)	(4.19)	(9.1E-4)	(9.56E-4)
Earnings Yield	(0.0588)	(0.29)	(0.28)	(0.3)	(1.1K)	(1.0K)
Current Ratio	6.82	15.71	4.55	2.53	0.00119	0.00113
Tangible Book Value Per Share	0.27	1.21	0.68	0.37	38.06	39.96
Shareholders Equity Per Share	0.27	1.21	0.68	0.37	38.06	39.96
Graham Net Net	0.27	1.19	0.65	0.36	(200.4)	(190.38)
Price Earnings Ratio	(17.01)	(3.48)	(3.56)	(3.33)	(9.33E-4)	(9.8E-4)
Price Book Value Ratio	28.96	3.56	5.89	10.4	0.0214	0.0203
Price To Operating Cash Flows Ratio	(23.34)	(8.81)	(5.71)	(4.95)	(0.001267)	(0.00133)
Price To Free Cash Flows Ratio	(23.34)	(8.81)	(5.71)	(4.95)	(0.001267)	(0.00133)
Company Equity Multiplier	1.19	1.07	1.28	1.65	6.27	6.59
Return On Capital Employed	(1.67)	(1.04)	(1.65)	(3.12)	(2.81)	(2.95)
Quick Ratio	6.82	15.71	4.55	2.53	0.00119	0.00113
Cash Ratio	6.72	15.36	4.42	2.46	0.001143	0.001086
Price To Book Ratio	28.96	3.56	5.89	10.4	0.0214	0.0203
Price Cash Flow Ratio	(23.34)	(8.81)	(5.71)	(4.95)	(0.001267)	(0.00133)
Return On Assets	(1.43)	(0.96)	(1.29)	(1.89)	(3.66)	(3.84)
Price Fair Value	28.96	3.56	5.89	10.4	0.0214	0.0203
Return On Equity	(1.7)	(1.02)	(1.65)	(3.12)	(22.93)	(21.78)

Pair Trading with Acurx Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acurx Stock

0.82

CDIOW

Cardio Diagnostics

Pair Corr

Moving against Acurx Stock

0.71	LUCD	Lucid Diagnostics	Pair Corr
0.63	WM	Waste Management	Pair Corr
0.49	GE	GE Aerospace	Pair Corr
0.34	PG	Procter Gamble Sell-off Trend	Pair Corr
0.32	PLX	Protalix Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.

The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Acurx Stock Analysis

When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Acurx Historical Financial Ratios

About Acurx Financial Ratios Analysis

Acurx Pharmaceuticals Financial Ratios Chart

Ptb Ratio

Book Value Per Share

Average Payables

Acurx Pharmaceuticals fundamentals Correlations

Acurx Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Acurx Pharmaceuticals fundamentals Accounts

Pair Trading with Acurx Pharmaceuticals

Moving together with Acurx Stock

Moving against Acurx Stock

Additional Tools for Acurx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Capex To Operating Cash Flow	+ 1.0	Book Value Per Share
Tangible Book Value Per Share	+ 1.0	Book Value Per Share
Shareholders Equity Per Share	+ 1.0	Book Value Per Share
Operating Cash Flow Per Share	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Free Cash Flow Yield

Capex Per Share	- 1.0	Shareholders Equity Per Share
Capex Per Share	- 1.0	Tangible Book Value Per Share
Shareholders Equity Per Share	- 1.0	Earnings Yield
Tangible Book Value Per Share	- 1.0	Earnings Yield
Capex Per Share	- 1.0	Capex To Operating Cash Flow
Earnings Yield	- 1.0	Capex To Operating Cash Flow